Valion Bio Q2 net loss widens to $7.1 million; operating loss deepens to $6.4 million

Valion Bio posted a GAAP net loss of $7.1 million for Q2 2026, widening from $1.93 million a year earlier.

GAAP operating loss widened to $6.42 million from $1.68 million, as total operating expenses climbed to $6.42 million from $1.68 million.

Research and development expense rose to $2.7 million from $655,000, while selling, general and administrative costs increased to $3.72 million from $1.02 million.

Cash and cash equivalents were $2.1 million at June 30, 2026; cash used in operating activities was $10.29 million for H1 2026.

Michael K. Handley became CEO in March; the company reported a 200x Entolimod manufacturing scale-up at 50-liter fermentation volume.